Controlled Release Dosage Form With Improved Bioavailability

Matrix Laboratories Limited
Granted App No 417/CHE/2010 Patent 309060 Pharmaceuticals

Patent information

IP India · live record
Application number
417/CHE/2010
Filing date
18 February 2010
Status
Granted
Legal status
Inforce
Publication number
46/2011
Publication type
INA
Invention field
Pharmaceuticals
Patent number
309060
Grant date
12 March 2019
Next renewal due
18 February 2027

Abstract

The invention relates to oral controlled release dosage form comprising an atypical antipsychotic agent. More particularly, the invention relates to oral controlled release dosage form comprising paliperidone or its pharmaceutically acceptable salts thereof and the process for preparing the same, wherein said dosage form exhibits improved bioavailability of paliperidone as compared to the commercially available invega®

Applicants

1
India
MATRIX LABORATORIES LIMITED 1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.

Inventors

6
India
REDDY, ANIL1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.
India
AMMINABAVI, NAGARAJ1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.
India
GORE, SUBHASH1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.
India
PANANCHUKUNNATH, MANOJ1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.
India
GUPTA, RAJESH1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.
India
BHUSHAN, INDU1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003.

Specification

Show full textCollapse

FIELD OF INVENTION

The invention relates to controlled release dosage form comprising an atypical antipsychotic agent.

More particularly, the invention relates to controlled release dosage form comprising paliperidone or its pharmaceutically acceptable salts thereof and the process for preparing the same.

BACKGROUND OF THE INVENTION AND RELATED PRIOR ART

Paliperidone is known as a major active metabolite of risperidone. It is chemically known as (±)-3-[2-[4- (6-fluoro-l, 2-benzisoxazol-3-yl)-l-piperidinyl] ethyl] -6, 7, 8, 9 -tetra hydro-9-hydroxy-2- methyl-4Hpyrido [1, 2-a] pyrimidin-4-one. It basically comprises a mixture of both (R) and (S) forms of risperidone and is disclosed in US 4,804,663 and 5,158,952.

Paliperidone is marketed under the trade name Invega in the form of extended release tablet in the U.S. and Europe for the treatment of acute (short-term) as well as maintenance (long-term) treatment of schizophrenia.

Paliperidone has a long half-life - about one day, so it is not a suitable drug for extended delivery. However, side effects such as anxiety, somnolence, dizziness, constipation, extra-pyramidal symptoms may be related to high blood plasma concentration levels restricting the ability to administer a single daily immediate release dose. Many efforts have been taken to control the release of the drug to provide extended release profile, while trying to control possible side-effects.

A number of design options are available to control or modulate the drug release from a dosage form, but osmotic system of delivery is found to be most preferred design to control the release of drug from dosage form as it is independent of pH, presence of food and other physiological factors with respect to other conventional controlled release system.

Commercially available Invega® is a capsule shaped tablet which consists of an osmotically active trilayer core surrounded by a subcoat and a semi¬permeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There are two precision laser-drilled orifices on the drug-layer dome of the tablet.

Patents / Patent applications, which disclose various osmotic controlled release compositions comprising paliperidone, are disclosed below:

U.S. 2004/0092534, U.S. 2005/0208132, U.S.2005/0232995, U.S. 2006/0189635, U.S. 2009/0202631 and U.S. 2009/0227605 disclose an oral dosage form wherein said dosage form comprises a dose D of a benzisoxazole and an oral sustained release dosing structure adapted to sustainably release the benzisoxazole derivative at rates that provide (a) a mean, single dose, maximum plasma concentration Cmax of the benzisoxazole derivative and pharmacologically active metabolites thereof taken together and (b) a mean, single dose, area under a plasma concentration-time curve for AUQnf of the benzisoxazole derivative and pharmacologically active metabolites thereof taken together, which satisfy the relationship about 0.5 ng/mL/mg

Documents

Sign in to open
Application documents
1 0417-che-2010 form-2 18-02-2010.pdf 18 Feb 2010
2 0417-che-2010 form-1 18-02-2010.pdf 18 Feb 2010
3 0417-che-2010 drawings 18-02-2010.pdf 18 Feb 2010
4 0417-che-2010 description(provisional) 18-02-2010.pdf 18 Feb 2010
5 0417-che-2010 correspondence others 18-02-2010.pdf 18 Feb 2010
6 417-che-2010 form-1 23-03-2010.pdf 23 Mar 2010
7 417-CHE-2010 FORM-3 23-03-2010.pdf 23 Mar 2010
8 417-CHE-2010 FORM-5 17-02-2011.pdf 17 Feb 2011
9 417-CHE-2010 FORM-2 17-02-2011.pdf 17 Feb 2011
10 417-CHE-2010 FORM-1 17-02-2011.pdf 17 Feb 2011
11 417-CHE-2010 DRAWINGS 17-02-2011.pdf 17 Feb 2011
12 417-CHE-2010 DESCRIPTION(COMPLETE) 17-02-2011.pdf 17 Feb 2011
13 417-CHE-2010 CORRESPONDENCE 17-02-2011.pdf 17 Feb 2011
14 417-CHE-2010 CLAIMS 17-02-2011.pdf 17 Feb 2011
15 417-CHE-2010 ABSTRACT 17-02-2011.pdf 17 Feb 2011
16 417-CHE-2010- FORM-13 13-05-2011.pdf 13 May 2011
17 417-CHE-2010- CORRESPONDENCE OTHERS 13-05-2011.pdf 13 May 2011
18 417-CHE-2010 FORM-18 13-05-2011.pdf 13 May 2011
19 417-CHE-2010 FORM-13 16-11-2011.pdf 16 Nov 2011
20 417-CHE-2010-FER.pdf 22 Mar 2017
21 417-CHE-2010-FER_SER_REPLY [11-09-2017(online)].pdf 11 Sep 2017
22 417-CHE-2010-COMPLETE SPECIFICATION [11-09-2017(online)].pdf 11 Sep 2017
23 Marked up Claims_Granted 309060_12-03-2019.pdf 12 Mar 2019
24 Drawings_Granted 309060_12-03-2019.pdf 12 Mar 2019
25 Description_Granted 309060_12-03-2019.pdf 12 Mar 2019
26 Claims_Granted 309060_12-03-2019.pdf 12 Mar 2019
27 Abstract_Granted 309060_12-03-2019.pdf 12 Mar 2019
28 417-CHE-2010-Written submissions and relevant documents (MANDATORY) [12-03-2019(online)].pdf 12 Mar 2019
29 417-CHE-2010-PatentCertificate12-03-2019.pdf 12 Mar 2019
30 417-CHE-2010-IntimationOfGrant12-03-2019.pdf 12 Mar 2019
31 417-CHE-2010-RELEVANT DOCUMENTS [30-03-2020(online)].pdf 30 Mar 2020
32 417-CHE-2010-FORM 4 [12-05-2021(online)].pdf 12 May 2021
33 417-CHE-2010-RELEVANT DOCUMENTS [29-09-2021(online)].pdf 29 Sep 2021
34 417-CHE-2010-RELEVANT DOCUMENTS [05-09-2022(online)].pdf 05 Sep 2022
35 417-CHE-2010-RELEVANT DOCUMENTS [28-07-2023(online)].pdf 28 Jul 2023
Search strategy
1417che2010searchpdf_07-03-2017.pdf

ERegister / renewals

Inforce
3rd Renewed 21 Mar 2019 Period 18 Feb 2012 – 18 Feb 2013 · CBR 9094 · Certificate 11294 ₹4,000
4th Renewed 21 Mar 2019 Period 18 Feb 2013 – 18 Feb 2014 · CBR 9094 · Certificate 11295 ₹4,000
5th Renewed 21 Mar 2019 Period 18 Feb 2014 – 18 Feb 2015 · CBR 9094 · Certificate 11296 ₹4,000
6th Renewed 21 Mar 2019 Period 18 Feb 2015 – 18 Feb 2016 · CBR 9094 · Certificate 11297 ₹4,000
7th Renewed 21 Mar 2019 Period 18 Feb 2016 – 18 Feb 2017 · CBR 9094 · Certificate 11298 ₹12,000
8th Renewed 21 Mar 2019 Period 18 Feb 2017 – 18 Feb 2018 · CBR 9094 · Certificate 11299 ₹12,000
9th Renewed 21 Mar 2019 Period 18 Feb 2018 – 18 Feb 2019 · CBR 9094 · Certificate 11300 ₹12,000
10th Renewed 21 Mar 2019 Period 18 Feb 2019 – 18 Feb 2020 · CBR 9094 · Certificate 11301 ₹12,000
11th Renewed 05 Feb 2020 Period 18 Feb 2020 – 18 Feb 2021 · CBR 4035 · Certificate 7554 ₹24,000
12th Renewed 12 May 2021 Period 18 Feb 2021 – 18 Feb 2022 · CBR 17472 · Certificate 30797 ₹24,000
13th Renewed 11 Feb 2022 Period 18 Feb 2022 – 18 Feb 2023 · CBR 5332 · Certificate 9343 ₹24,000
14th Renewed 16 Feb 2023 Period 18 Feb 2023 – 18 Feb 2024 · CBR 7176 · Certificate 12533 ₹24,000
15th Renewed 13 Feb 2024 Period 18 Feb 2024 – 18 Feb 2025 · CBR 9350 · Certificate 27332 ₹24,000
16th Renewed 06 Feb 2025 Period 18 Feb 2025 – 18 Feb 2026 · CBR 6688 · Certificate 9614 ₹40,000
17th Renewed 05 Feb 2026 Period 18 Feb 2026 – 18 Feb 2027 · CBR 8524 · Certificate 9291 ₹40,000